News | November 01, 2022
Aptar Pharma completes Phase I global injectables expansion program
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
The company is committed to addressing the observations at the earliest, and gaining approval for injectable manufacturing for the US
The observation is procedural in nature and the company will address the observation within stipulated timelines.
He has over 23 years' experience working in leading companies such as Omniactive Health Technologies, Johnson Matthey Chemicals, BASF, Godrej Agrovet Limited & Bharat Petroleum Corporation Limited.
Indigenously-developed molecular diagnostics have helped expand the reach of diagnosis to every part of the country today
He also encouraged all G20 members to contribute their public keys to the proposed Global Federated Public Trust Directory for ensuring seamless worldwide mobility of people and goods
It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.
The CRL did not identify any outstanding scientific issues with the product.
Frazier led the company for 10 years as President and Chief Executive Officer, from 2011 through 2021.
Subscribe To Our Newsletter & Stay Updated
